How often cancer returns depends heavily on the type of cancer, the stage at diagnosis, and the treatment received. Across major solid tumors, recurrence rates range from roughly 14% to over 50%, with most recurrences appearing within the first three years after treatment. Understanding the numbers for specific cancers, and what influences them, can help you make sense of your own risk.
What Recurrence Actually Means
A cancer recurrence is the return of the same original cancer after a period when no disease could be detected. It can show up in the same location (local recurrence), in nearby lymph nodes (regional recurrence), or in a distant organ like the lungs, liver, or bones (distant recurrence). Distant recurrence is the most serious because it means cancer cells traveled through the bloodstream or lymphatic system to a new site.
This is different from developing a second, entirely new cancer. Distinguishing between the two is not always straightforward. If a tumor reappears shortly after treatment ends, especially within a few months, it may actually be a persistent cancer that was never fully eliminated rather than a true recurrence. Clinicians use the tumor’s genetic profile and location to sort this out, but the line can be blurry.
Breast Cancer
Breast cancer recurrence rates vary dramatically by subtype. In node-negative (early-stage) disease, a large analysis from the International Breast Cancer Study Group found these 10-year recurrence rates:
- Hormone receptor-positive, HER2-negative (Luminal A-like): about 14% recurrence at 10 years
- Hormone receptor-positive, HER2-negative (Luminal B-like): about 24%
- HER2-positive: about 27%
- Triple-negative: about 29%
Where the cancer returns also differs by subtype. Triple-negative and HER2-positive breast cancers are significantly more likely to recur in internal organs. In contrast, hormone receptor-positive cancers have a higher tendency to recur in the bones. One important feature of hormone receptor-positive breast cancer is that it can come back many years, even decades, after the original diagnosis. For most other subtypes, the risk drops substantially after the first few years.
Prostate Cancer
After surgical removal of the prostate, recurrence is tracked by rising PSA levels, a marker called biochemical recurrence. In a large study of men followed for over a decade after surgery, biochemical recurrence rates were 16% at 5 years and 28% at 10 years. A more recent series of nearly 2,500 patients found even higher long-term numbers: 34% at 10 years, 44% at 15 years, and 53% at 20 years.
These numbers need context, though. A rising PSA level does not always mean the cancer has spread or will ever cause symptoms. Many men with biochemical recurrence live for years or decades without needing further treatment. The speed at which PSA rises, known as the doubling time, is one of the most important factors in determining whether a biochemical recurrence is something that needs aggressive treatment or simply careful monitoring.
Lung Cancer
Non-small cell lung cancer, the most common form, has recurrence rates of 30% to 55% even after surgery intended to be curative. This wide range reflects how much stage matters. A small, early-stage tumor confined to one area of the lung has a much lower recurrence risk than a larger tumor or one that has reached nearby lymph nodes.
Lung cancer recurrences tend to appear relatively quickly. Most show up within the first two years after surgery, which is why follow-up imaging is typically scheduled more frequently during that window.
Melanoma
For melanoma patients whose sentinel lymph node biopsy was negative (meaning no cancer was found in the nearest lymph nodes), recurrence rates depend on how thick the original tumor was:
- Thin melanomas (1 mm or less): 14% recurrence
- 1 to 2 mm thick: 32%
- 2 to 4 mm thick: 36%
- Greater than 4 mm: 17%
The drop at the thickest category may seem surprising. It likely reflects the biology of very thick tumors in patients who still had negative lymph nodes, a combination that selects for less aggressive disease. When melanoma does spread to lymph nodes at diagnosis, recurrence rates climb considerably higher.
When Recurrence Risk Is Highest
For most solid tumors, the risk of recurrence rises steeply during the first three years after treatment and then levels off. This pattern holds across many cancer types and is the reason oncologists schedule the most intensive follow-up visits during years one through three. After the five-year mark, the annual risk of recurrence drops significantly for most cancers.
Breast cancer is the notable exception. Hormone receptor-positive breast cancers can recur 10, 15, or even 20 years after the original diagnosis, which is why some patients take hormone-blocking medications for a decade or more. If you had this subtype, continued surveillance matters even when you’re well past the five-year milestone.
How Exercise Affects Recurrence Risk
Regular physical activity after a cancer diagnosis is one of the few modifiable factors with clear evidence behind it. A study published in the Journal of Clinical Oncology involving over 9,000 breast cancer patients found that exercising at a moderate level (roughly equivalent to brisk walking for about 2.5 hours per week) was associated with an 18% lower risk of distant recurrence compared to being largely inactive.
The benefit was strongest for certain subtypes. Premenopausal women who exercised at this threshold had a 36% lower risk of distant recurrence. For triple-negative breast cancer, the risk reduction was roughly 40%, and for HER2-positive, hormone receptor-negative cancers, the reduction was as high as 63%. Interestingly, increasing exercise beyond about 25 MET-hours per week (roughly five hours of brisk walking or three hours of jogging) did not provide additional benefit. In postmenopausal women, the study did not find a clear association between exercise and recurrence reduction.
How Recurrence Is Detected
Most recurrences are caught through a combination of routine imaging (CT scans, MRIs, PET scans) and blood tests for tumor markers like PSA or CEA, depending on the cancer type. The schedule of these follow-up tests is typically most frequent in the first two to three years, then gradually spaces out.
A newer approach uses blood tests that look for fragments of tumor DNA circulating in the bloodstream. These liquid biopsies can sometimes detect molecular signs of recurrence before anything shows up on a scan. In lung cancer, one study found this method had a sensitivity of 78% and a specificity of 99% for detecting cancer that had returned outside the brain. This technology is still being integrated into routine care, but it represents a shift toward catching recurrence earlier, when it may be more treatable.
Factors That Influence Your Individual Risk
The numbers above are population averages. Your personal recurrence risk is shaped by several factors that interact with each other: the stage at diagnosis, whether surgical margins were clear of cancer cells, the tumor’s genetic profile, whether you completed the full course of recommended treatment, and your overall health. Cancers that respond completely to initial treatment generally have lower recurrence rates than those that showed only a partial response.
Your oncologist can provide a more tailored estimate using tools like genomic assays for breast cancer or nomograms for prostate cancer. These tools combine multiple features of your specific cancer into a single risk score, which is far more useful than general statistics for guiding decisions about additional treatment or the intensity of follow-up care.